Clinical Trial: RWE Non-Interventional Prospective Study of Ribociclib Effectiveness and Safety in Patients With HR+/HER2- Early Breast Cancer in Saudi Arabia

U.S., Jan. 29 -- ClinicalTrials.gov registry received information related to the study (NCT06797531) titled 'RWE Non-Interventional Prospective Study of Ribociclib Effectiveness and Safety in Patients With HR+/HER2- Early Breast Cancer in Saudi Arabia' on Jan. 21.

Brief Summary: This is a non-interventional, prospective, single-arm, observational study describing the real-world effectiveness, safety, and PRO and HCRU data of ribociclib combined with adjuvant ET under conditions of routine clinical practice in HR+/HER2- EBC in premenopausal, perimenopausal and postmenopausal women, or men in Saudi Arabia.

Study Start Date: March 31

Study Type: OBSERVATIONAL

Condition: HR+/HER2- Early Breast Cancer

Intervention: DRUG: ribociclib

This ...